Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY26)

Nature of Filing / Announcement: Unaudited Financial Results under SEBI LODR Regulations 30 and 33

Audit Opinion:

Unmodified review conclusion by statutory auditors Walker Chandiok & Co LLP

Auditor’s Comment:

No qualifications or modifications. The limited review did not identify any material misstatements in the financial results.

Key Financial Highlights [₹ in Million]:

Standalone Results:

Revenue from Operations: ₹6,404.14 (Q1 FY26) vs ₹6,018.46 (Q1 FY25) - 6.4% YoY increase

Total Income: ₹6,628.15 (Q1 FY26) vs ₹6,108.31 (Q1 FY25)

Net Profit: ₹1,600.76 (Q1 FY26) vs ₹1,215.35 (Q1 FY25) - 31.7% YoY increase

EPS (Basic): ₹13.04 (Q1 FY26) vs ₹9.91 (Q1 FY25)

EPS (Diluted): ₹13.01 (Q1 FY26) vs ₹9.88 (Q1 FY25)

Paid-up Equity Share Capital: ₹245.48 million (122,739,448 equity shares of face value ₹2 each)

Other Equity: ₹33,075.85 million (as of March 31, 2026)

Expense Breakdown:

Cost of materials consumed: ₹2,531.46

Employee benefits expense: ₹682.45

Finance costs: ₹13.07

Depreciation and amortization expenses: ₹205.85

Other expenses: ₹1,054.11

Total expenses: ₹4,505.92

Tax Expenses:

Current tax: ₹502.74

Deferred tax: ₹18.73

Total tax expenses: ₹521.47

Other Comprehensive Income:

Re-measurement of post-employment benefit obligation: ₹4.12

Income tax relating to the above: (₹1.04)

Total other comprehensive income after tax: ₹3.08

Total Comprehensive Income:

₹1,603.84 (Q1 FY26) vs ₹1,212.31 (Q1 FY25)

Segment-wise Performance:

The Company has identified only one reporting segment: Active Pharmaceutical Ingredient (API)

Corporate Actions:

Allotment of 3,100 equity shares of ₹2 each pursuant to "Employee Stock Option Scheme, 2021" during the quarter ended June 30, 2026

542,531 options outstanding under Employee Stock Option Plan 2021 as of June 30, 2026

Other Significant Information:

Exceptional items for year ended March 31, 2026 included incremental effect of new labour codes: ₹256.57 million (Gratuity: ₹170.02 million + Compensated absences: ₹86.55 million)

Figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and unaudited year-to-date figures